Its expression in normal cells is considerably lower compared to specific cancer cells such as pancreatic cancer, mesothelioma, ovarian and extra bile duct tumors, lung adenocarcinomas, and stomach cancers (27) This differential mesothelin expression in healthy tissues makes it an attractive target for cancer immunotherapy specific to these tumors (142). This evidence concerns the gene MSLN and gastric cancer.